The Role of Circulating Tumor DNA in Early Detection of HER2-positive Breast Cancer

Abstract

Breast cancer remains one of the major global health challenges, the Human Epidermal Receptor-2 (HER-2) subtype is characterized by aggressive tumor growth due to overexpression of the HER2-positive. Early detection of HER2-positive breast cancer is crucial for improving patient’s outcomes and reducing the risk of metastatic disease. Circulating Tumor DNA is DNA fragments which are released by cancer cells into the bloodstream, and has emerged as a promising non-invasive biomarker for early cancer detection. This review will explore the role of ctDNA in the early detection of HER2-positive breast cancer and its role in prognosis. Studies have shown the high relevance of ctDNA as a diagnostic biomarker, particularly in early-stage disease. Multiple studies have evaluated the role of ctDNA in breast cancer patients, which results consistently showed a strong relation between ctDNA detection and early-stage disease. Additionally, research has indicated that high ctDNA levels are related with a higher risk of recurrence and poorer survival outcomes. The non-invasive nature of ctDNA testing offers several advantages compared to traditional methods, including the ability of monitoring disease progression and treatment response without any need for invasive procedures. Early detection of HER2-positive breast cancer through ctDNA analysis can potentially improve patient outcomes by enabling timely intervention and targeted therapies. By identifying patients with high risk and monitoring disease status, ctDNA testing may contribute to more effective management of HER2-positive breast cancer. While ctDNA analysis shows great promise, it is also important to acknowledge the current limitations and challenges associated with its clinical application. Issues such as standardization of detection methods, sensitivity, and specificity need to be addressed to ensure the widespread adoption of ctDNA testing in routine clinical practice. In conclusion, ctDNA represents a promising biomarker for the early detection and management of HER2-positive breast cancer. Further research and advancements in ctDNA analysis are essential to completely realize its potential and improve patient outcomes.